Influenza
Conditions
Keywords
vaccine, influenza vaccine, older adults, vaccine response, toll-like receptors, immune response
Brief summary
This study will compare the immune response signatures (including immunologic, transcriptomic and metabolomic) of the two influenza vaccines approved for use in adults age 65 and over (Fluad and Fluzone High-Dose).
Detailed description
There are two vaccines currently approved for use in adults age 65 and greater: a high-dose (HD) influenza vaccine (Fluzone High-Dose) that contains 4 times the hemagglutinin dose found in the standard vaccine, and a standard-dose (SD) vaccine containing the proprietary MF59 adjuvant (Fluad). Both vaccines give significantly highly antibody responses to influenza in older adults. This study will directly compare the HD and SD vaccines in nursing home residents, the population of older adults most vulnerable to influenza outbreaks and morbidity and mortality. It will comprehensively study the innate and adaptive response to vaccination, as well as elucidate transcriptomic and proteomic signatures of vaccine response. This is a randomized, open label study comparing the two vaccines currently approved for use in adults age ≥ 65 years: the high-dose influenza vaccine and the MF59 adjuvanted standard-dose vaccine, both quadrivalent. The young group will be comprised of individuals 21-30 years of age, and the older cohorts will consist of nursing home residents ≥65 years. Participants will also be evaluated for evidence of influenza-like illness (ILI). ILI is defined to include clinical presentation in older adults: by the presence of either two respiratory symptoms (cough, sore throat, shortness of breath, and nasal stuffiness) or one respiratory and one systemic symptom (headache, malaise, temperature \>99° F, report of feverishness and muscle aches, or altered mental status). Diagnoses of influenza will be confirmed using a real-time polymerase chain reaction (PCR) test on a nasopharyngeal (NP) swab specimen done by the hospital Virology Laboratory and facilitated by the participating medical directors. Although this is neither an efficacy or effectiveness study, participants will be randomized 1:1 to either the high-dose influenza vaccine or the MF59 vaccine within age strata. This will ensure a non-biased allocation of the two vaccines and attempts to balance participant characteristics within age strata.
Interventions
BIOLOGICALFluzone
Fluzone High-Dose 0.7 ml intramuscular injection, standard as recommended by manufacturer
BIOLOGICALFluad
Fluad Quadrivalent, MF59 adjuvanted 0.5 ml intramuscular injection, standard as recommended by manufacturer
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Yale University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age 21-40 or 65 and older * Ability to understand and give informed consent (surrogate consent may apply to nursing home subjects who are decisionally impaired, with verbal assent to be obtained from subject) * Plan to be in the New Haven, CT area for the next 4-6 weeks
Exclusion criteria
* Current use of medication, such as antibiotics in past two weeks. To clarify, patients taking antibiotics for the reason of a current acute infection will not be eligible. Those potential participants receiving antibiotics for prophylaxis purposes will be eligible to participate. The intention is not to create a separate group to drawn conclusions, but not to exclude these participants who are not acutely ill. * Evidence of acute infection, identified by self- report of fever or symptoms in past two weeks * Treatment for cancer in past three months. * Previous adverse reaction to influenza vaccine requiring medical attention, such as allergic response (rash, anaphylaxis) or Guillain-Barré syndrome. * Pregnant/possibly pregnant. * History of organ, bone marrow or stem cell transplant, liver cirrhosis, kidney disease requiring dialysis, HIV/AIDS, hepatitis C or active hepatitis B * Blood donation of 1 pint or more in past 2 months * Treatment with clinical trial medication * Presence of any other condition (e.g., geographical or social), actual or projected, that the investigator feels would restrict or limit the patient's participation for the duration of the study. This provision includes participants who have 50% or more missed appointments in the last three months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in production of IL-6 in monocytes to assess innate immune inflammatory response | Baseline and at Day 2, 7, and 28 post-vaccine | Measurement of IL-6 production in monocytes via flow cytometry |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Hemagglutination inhibition titer (HAI) in response to vaccination | Baseline and Day 28 | HAI titers levels in blood measured prior to and at day 28 post-vaccine |
| Change in transcriptomic analyses of gene expression | At Baseline, Day 2, Day 7, Day 28 and Day 70 | RNA-seq analysis of RNA derived from peripheral blood mononuclear cells (PBMCs) and platelet-rich plasma (PRP) |
| Change in proteomic analyses | At Baseline, Day 2, Day 7, Day 28 and Day 70 | Analysis of protein expression using Mass Spectrometry in plasma |
| Number of participants with changes in innate immune function from PBMCs and PRP as assessed using flow cytometry | At Baseline, Day 2, Day 7, Day 28 and Day 70 | Analyses will include intracellular production of cytokines including IL-10 and TNF-alpha in monocyte populations from PBMCs and expression of platelet activation markers such as CD63 and P-selectin on platelets. The effects of ex vivo Toll-like Receptor stimulation on these parameters will also be assessed. |
| Number of participants with changes in B and T cell function from PBMCs as assessed using flow cytometry | At Baseline, Day 2, Day 7, Day 28 and Day 70 | This will include analysis of number and proportion of antibody-secreting cells post-vaccine, and analyses of T cells following ex vivo stimulation of PBMCs with influenza hemagglutinins. |
Countries
United States
Contacts
Primary ContactIrene Matos, RN
Outcome results
None listed